Hostname: page-component-586b7cd67f-t8hqh Total loading time: 0 Render date: 2024-11-25T17:27:39.148Z Has data issue: false hasContentIssue false
  • English
  • Français

A Monoamine Oxidase Inhibitor (Niamid) in the Treatment of the Mentally Subnormal

Published online by Cambridge University Press:  08 February 2018

T. S. Davies
T. S. Davies*
Affiliation:
Llanfrechfa Grange Hospital, Newport, Mon
Get access Rights & Permissions [Opens in a new window]

Extract

A clinical evaluation of the effects of a recently introduced monoamine oxidase inhibitor, N - isonicotinoyl - N1—(β - N - benzylcarboxamido - ethyl) hydrazine (Niamid, Pfizer, Ltd.) on certain types of mentally subnormal patients has been carried out over the past year.

Type
Original Articles
Information
Journal of Mental Science , Volume 107 , Issue 446 , January 1961 , pp. 115 - 118
Copyright
Copyright © Royal College of Psychiatrists, 1961 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)
Submit a response

eLetters

No eLetters have been published for this article.